3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Thoracic
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
6
Uterine Cervical Neoplasms
5
Head and Neck Neoplasms
5
Vaginal Neoplasms
4
Penile Neoplasms
4
Oropharyngeal Neoplasms
4
Neoplasm Metastasis
4
Anus Neoplasms
4
Stomach Neoplasms
3
Melanoma
3
Carcinoma, Squamous Cell
3
Carcinoma, Non-Small-Cell Lung
3
Vulvar Neoplasms
2
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Small Cell Lung Carcinoma
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Sarcoma
1
Interventions
pembrolizumab
20
Docetaxel
8
Carboplatin
8
Fluorouracil
6
Cisplatin
6
Nivolumab
5
fludarabine
4
Trastuzumab
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Cyclophosphamide
4
Biopsy
4
Bevacizumab
4
fludarabine phosphate
3
durvalumab
3
atezolizumab
3
Taxes
3
Radiotherapy
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
ulixertinib
2
tisotumab vedotin
2
spartalizumab
2
belinostat
2
adavosertib
2
X-Rays
2
Vorinostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
aldesleukin
×
Head & Neck
×
Clear all
NCT02876510
2025-02-04
ACTolog
Immatics US, Inc.
Phase 1
Completed
38 enrolled